ENA Respiratory

Private

MelbourneHealthcare & Life Scienceshttps://enarespiratory.com/

Last Round

Series B

Oct 22, 2025

Total Funding Raised

$46.83M

Company Overview

ENA Respiratory is a clinical-stage pharmaceutical company developing antiviral host defence enhancers to combat respiratory viral infections by boosting the body's local innate immune response.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

innate immune boosterantiviral nasal sprayprophylactic therapyTLR2/6 agonistrespiratory virus preventionclinical-stage biotechinnate immunitynasal dry powdervirus-agnostic therapyimmune primingpandemic preparednessbiopharmadrug developmentimmune health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ENA Respiratory Comps

Public and private peers based on sector, stage, and business model.

ENA Respiratory comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ENA Respiratory Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series B	Oct 22, 2025
Grant	Sep 5, 2024
Grant	Aug 29, 2023
Grant	Jan 9, 2023
VC Round	Jun 15, 2021
Series A Extension	Sep 28, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Christophe Demaison

Managing Director and CEO

Executive Team

ENA Respiratory Investors

Notable investors and investment history

ENA Respiratory investors
Investor	Rounds
Flu Lab	Series B
Minderoo Foundation	VC Round
United States Department of Defense	Grant
Hostplus Superannuation Fund	Series A Extension
Bill & Melinda Gates Foundation	Series B
Uniseed	Series A, Series A Extension, Series B, VC Round
Stoic Venture Capital	Series A Extension, Series B

View all Investors

ENA Respiratory Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

ENA Respiratory Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ENA Respiratory's valuation, stock price, and market status.

Firmographic Details

HeadquartersMelbourne

Employee Range9

Year Founded2014

Last FundingOct 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.